Movement Alert｜RemeGen Falls 5.06% in Regular Trading, Biotech Sector Broadly Weakens Amid Continued Lock-up Expiry Pressure

Market Focus07-17

On July 17, RemeGen fell 5.06% in regular trading, trading at HK$78.7/share, with turnover of HK$124 million.

The decline was driven by broad weakness across the biotech sector and continued selling pressure following the company's massive lock-up share release. The wider biotech space saw significant losses, with Akeso down 8.6%, 3SBIO down 7.71%, and BeiGene down 2.31%.

On the company-specific front, RemeGen completed the release of 193 million previously restricted shares on July 1, representing 34.16% of total share capital. Since then, selling pressure has persisted, with the A-share experiencing a 20% limit-down and consecutive sharp declines during July 9-10, with the cumulative three-day deviation exceeding 30%. The controlling shareholder subsequently announced plans to increase holdings by RMB 10-20 million, but market sentiment recovery has remained limited.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112177241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112177241","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Falls 5.06% in Regular Trading, Biotech Sector Broadly Weakens Amid Continued Lock-up Expiry Pressure","media":"Market Focus","content":"<p><p>On July 17, RemeGen fell 5.06% in regular trading, trading at HK$78.7/share, with turnover of HK$124 million.</p><p>The decline was driven by broad weakness across the biotech sector and continued selling pressure following the company's massive lock-up share release. The wider biotech space saw significant losses, with Akeso down 8.6%, 3SBIO down 7.71%, and BeiGene down 2.31%.</p><p>On the company-specific front, RemeGen completed the release of 193 million previously restricted shares on July 1, representing 34.16% of total share capital. Since then, selling pressure has persisted, with the A-share experiencing a 20% limit-down and consecutive sharp declines during July 9-10, with the cumulative three-day deviation exceeding 30%. The controlling shareholder subsequently announced plans to increase holdings by RMB 10-20 million, but market sentiment recovery has remained limited.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Falls 5.06% in Regular Trading, Biotech Sector Broadly Weakens Amid Continued Lock-up Expiry Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Falls 5.06% in Regular Trading, Biotech Sector Broadly Weakens Amid Continued Lock-up Expiry Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, RemeGen fell 5.06% in regular trading, trading at HK$78.7/share, with turnover of HK$124 million.</p><p>The decline was driven by broad weakness across the biotech sector and continued selling pressure following the company's massive lock-up share release. The wider biotech space saw significant losses, with Akeso down 8.6%, 3SBIO down 7.71%, and BeiGene down 2.31%.</p><p>On the company-specific front, RemeGen completed the release of 193 million previously restricted shares on July 1, representing 34.16% of total share capital. Since then, selling pressure has persisted, with the A-share experiencing a 20% limit-down and consecutive sharp declines during July 9-10, with the cumulative three-day deviation exceeding 30%. The controlling shareholder subsequently announced plans to increase holdings by RMB 10-20 million, but market sentiment recovery has remained limited.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1112177241","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112177241","pubTimestamp":1784253756,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, RemeGen fell 5.06% in regular trading, trading at HK$78.7/share, with turnover of HK$124 million.The decline was driven by broad weakness across the biotech sector and continued selling...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"走势警报|RemeGen 常规交易中下跌 5.06%，生物技术板块因锁定到期压力持续而普遍走弱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 17, RemeGen fell 5.06% in regular trading, trading at HK$78.7/share, with turnover of HK$124 million.The decline was driven by broad weakness across the biotech sector and continued selling pressure following the company's massive lock-up share release. The wider biotech space saw significant losses, with Akeso down 8.6%, 3SBIO down 7.71%, and BeiGene down 2.31%.On the company-specific front, RemeGen completed the release of 193 million previously restricted shares on July 1, representing 34.16% of total share capital. Since then, selling pressure has persisted, with the A-share experiencing a 20% limit-down and consecutive sharp declines during July 9-10, with the cumulative three-day deviation exceeding 30%. The controlling shareholder subsequently announced plans to increase holdings by RMB 10-20 million, but market sentiment recovery has remained limited.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112177241","isCrawlerRequest":true}